A5036280254- Vitamin D Research Studies
- Erythropoietin and Anemia Treatment
- Parathyroid Disorders and Treatments
- Dialysis and Renal Disease Management
- Renal Diseases and Glomerulopathies
- Hemophilia Treatment and Research
- Hemoglobinopathies and Related Disorders
- Iron Metabolism and Disorders
- Blood Coagulation and Thrombosis Mechanisms
- Erythrocyte Function and Pathophysiology
- Genetic Syndromes and Imprinting
- Bone health and osteoporosis research
- Work-Family Balance Challenges
- Cardiac Ischemia and Reperfusion
- Liver Disease Diagnosis and Treatment
- Adipokines, Inflammation, and Metabolic Diseases
- Blood Pressure and Hypertension Studies
- Bipolar Disorder and Treatment
- Bone health and treatments
- Complement system in diseases
- Biochemical effects in animals
- Anesthesia and Neurotoxicity Research
- Magnesium in Health and Disease
- Vitamin C and Antioxidants Research
- Chemokine receptors and signaling
Chugai Pharma (United States)
1998-2016
Hiroshima University
2012-2013
Eloxx Pharmaceuticals (United States)
2003
Tokushima University
2003
Tokyo Teishin Hospital
1999
The University of Tokyo
1999
Tokai University
1999
Tohoku Medical and Pharmaceutical University
1989-1990
Fibroblast growth factor-23 (FGF-23), a novel phosphate-regulating factor, was elevated in hypophosphatemic patients with X-linked rickets/osteomalacia and also chronic kidney disease. These observations suggested the pathophysiological importance of FGF-23 on phosphate homeostasis. However, regulation production is still unclear. We investigated effects both dietary phosphorus 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) circulating vivo Administration of. 1α,25(OH)2D3 dose-dependently...
The human fibroblast growth factor 23 (hFGF23) and its autosomal dominant hypophosphatemic rickets (ADHR) mutant genes were incorporated into animals by naked DNA injection to investigate the action on phosphate homeostasis <i>in vivo</i>. hFGF23 mutants (R176Q, R179Q, R179W) markedly reduced serum phosphorus (6.2–6.9 mg/dl) compared with plasmid MOCK (8.5 mg/dl). However, native did not affect (8.6 Both hFGF23R179Q mRNAs expressed more than 100-fold in liver 4 days after injection, however,...
Diabetic nephropathy is a major risk of end-stage kidney disease. Many complex factors relate to the progression diabetic nephropathy. Using nonobese type 2 diabetes model rats, we confirmed that oxidative stress was crucial factor. Because recent studies suggest vitamin D could suppress stress, explored whether active analog, maxacalcitol, also attenuate and prevent rats aged 20 weeks were divided into 3 groups treated with insulin, vehicle. At age 30 weeks, blood urine analyses, renal...
Vitamin D deficiency is associated with endothelial dysfunction in type 2 diabetes patients, but the effectiveness of vitamin supplementation remains controversial. We assessed whether 22-oxacalcitriol (OCT) could prevent mellitus (DM) rats. DM rats early-stage nephropathy were treated for 10 weeks OCT (0.2 μg/kg) three times per week or by an implanted insulin pellet. Endothelial was femoral flow-mediated dilation (FMD). Insulin significantly improved FMD as blood glucose levels normalized....
Background. 22‐Oxacalcitriol (OCT), an analogue of vitamin D, has been shown to inhibit cell proliferation in cultured mesangial cells. OCT also prevented albuminuria and glomerular injury acute model anti‐Thy1 glomerulonephritis. However, potential side effects, including calcaemic actions tubular dysfunction, chronic treatment remain unclear. In the present study, we evaluated effect a progressive glomerulosclerosis subtotally nephrectomized (SNX) rats.
Bone fractures markedly reduce quality of life and expectancy in elderly people. Although osteoporosis increases bone fragility, frequently occur patients with normal mineral density. Because most on falling, preventing falls is another focus for reducing fractures. In this study, we investigated the role vitamin D receptor (VDR) signaling locomotive ability. rotarod test, physical exercise enhanced ability wild-type (WT) mice by 1.6-fold, whereas did not enhance VDR knockout (KO) mice....
Although it effectively suppresses parathyroid hormone (PTH) secretion, vitamin D [1,25(OH)(2)D(3)] therapy often causes tissue calcification over the long term. In patients on chronic dialysis, cardiovascular is clearly linked to an unfavourable prognosis. pre-dialysis patients, renal of kidney leads deterioration function.We compared propensities 22-oxacalcitriol (OCT), with lesser calcaemic action, and 1,25(OH)(2)D(3) for producing their potential side effects in rats: (i) metastatic...
<b><i>Background/Aims:</i></b> Vascular disease is one of the critical complications diabetes. A growing body evidence suggests that oxidative stress plays a key role for vascular progression. Recent studies have demonstrated strong link between vitamin D and cardiovascular disease. <b><i>Methods:</i></b> We investigated anti-oxidative effects analog, 22-oxacalcitriol (maxacalcitol), on lesions in type 2 diabetic rats. used Spontaneously...
Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab recognizes FIX/FIXa FX/FXa, question may arise whether competes with antithrombin (AT) and/or tissue pathway inhibitor (TFPI), thereby enhancing overall hemostatic potential by blocking their antihemostatic effects. To address this question, we performed enzymatic assays using purified coagulation factors confirm interferes action AT...
Abstract The effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogue 22-oxa-1,25(OH)2D3 (22-oxacalcitriol) (OCT) on calcium bone metabolism were examined in an animal model hypercalcemia with continuous infusion parathyroid hormone–related peptide (PTHrP), to determine whether active vitamin D could counteract the skeletal action PTHrP addition reported effect suppressing production cancer cells. Parathyroid glands removed from 8-week-old Sprague–Dawley rats eliminate confounding...
Abstract Introduction Emicizumab is an antifactor (F)IXa/FX bispecific antibody, mimicking FVIIIa cofactor function. Emi prophylaxis effectively reduces bleeding events in patients with haemophilia A. The physical properties of emicizumab‐induced fibrin clots remain to be investigated, however. Aim We have investigated the stability and structure clots. Methods Coagulation was initiated by activated partial thromboplastin time (aPTT) trigger prothrombin (PT)/aPTT‐mixed FVIII‐deficient plasma...
Background. Since Slatopolsky et al. (J Clin Invest 1984; 74: 2136–2143) reported the effect of active vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), on secondary hyperparathyroidism (2HPT) which accompanies chronic renal failure, there have been several studies therapeutic effects 1,25(OH)2D3 in this disease. Although parathyroid hormone (PTH) is suppressed by treatment with 1,25(OH)2D3, long-term tends to induce hypercalcaemia. Therefore, an analogue 1,25-dihydroxy-22-oxavitamin...
<b><i>Background/Aims:</i></b> Recent studies have demonstrated that erythropoiesis-stimulating agents (ESAs) induce a tissue-protective effect in the kidney. In this study, we examined whether continuous erythropoietin receptor activator (CERA), long-acting ESA, could prevent kidney injury, especially podocyte damage, rat model of nephrotic syndrome induced by puromycin aminonucleoside (PAN). <b><i>Methods:</i></b> Rats were injected with CERA...
Abstract Background Emicizumab prophylaxis is a promising treatment that reduces bleeding events in severely affected patients with hemophilia A (PwHA). It anticipated emicizumab could be similarly effective mild/moderate PwHA (PwMHA) although this effect has not been investigated. Aim We evaluated ex vivo coagulant effects of emicizumabin PwMHA. Methods Clot waveform analysis (CWA) triggered by prothrombin time/activated partial time-mixed reagents was utilized to examine factor...